Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hana Vaknin-Assa has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Eyeballing versus comprehensive geriatric frailty assessment and outcomes after transcatheter aortic valve replacement: Insights from a large cohort

    by Ziad Arow, Juri Iwata, Akiko Masumoto, Antonella Millin, Amir Aker, Hana Vaknin-Assa, Abid Assali, Chiara De Biase, Nicolas Dumonteil, Didier Tchetche


  • Open Access

    Sex Differences in Long-Term Outcomes of Left Atrial Appendage Closure—Analysis from the LEADER Registry

    by Aviad Rotholz, Hagai Itach, Roi Ferman, Tsahi T. Lerman, Avi Sabbag, Israel M. Barabash, Ehud Chorin, Roei Merin, Hana Vaknin Assa, Alexander Omelchenko, et al.

    Background: Percutaneous left atrial appendage closure (LAAC) provides an alternative to oral anticoagulation (OAC) in atrial fibrillation (AF) patients who are at high bleeding risk. Prior studies have suggested sex-related differences in procedural outcomes, with women demonstrating higher peri-procedural complication rates. Data on long-term outcomes, however, remain inconsistent. Methods: We analyzed 407 consecutive patients with AF who underwent LAAC between 2010 and 2023 in four Israeli medical centers participating in the LEADER registry. Baseline characteristics, procedural data, and clinical outcomes were compared between men and women. The primary efficacy endpoint was ischemic stroke or systemic embolism at 1 year. The primary safety endpoint was a composite of all-cause mortality, procedural complications, or major bleeding at 1 year. Results: Of 407 patients, 285 (70%) were men and 122 (30%) were women. The mean age was 77 ± 8.4 years with similar CHA2DS2-VASc and HAS-BLED scores across sexes. Device implantation exceeded 99% in both sexes. Major peri-procedural complications occurred in 6.4% overall, without significant sex-based differences (men 7.0%, women 4.9%, p = 0.51). At 1-year follow-up, Kaplan–Meier estimates for the primary efficacy endpoint of ischemic stroke/systemic embolism (2.6%), the primary safety endpoint (19.2%), major bleeding (8.9%), and all-cause mortality (9.3%) were comparable between men and women (all p > 0.1). Conclusions: In contrast to prior large registries reporting higher peri-procedural risk in women, this real-world multicenter experience demonstrated no significant sex differences in either peri-procedural or long-term outcomes following LAAC. These findings support LAAC as an effective and safe stroke-prevention strategy in AF, irrespective of sex.


  • Open Access

    Sex-Based Differences in SGLT2i and GLP-1RA Use and Mortality in T2DM with Atherosclerotic Cardiovascular Disease

    by Hana Vaknin-Assa, Ammie Wolf, Ranin Hilu, Ela Giladi, Mustafa Gabarin, Ilya Losin, Yoav Arnson, David Pereg, Abid Assali, Ziad Arow

    Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) remain underused in routine practice, particularly among women. Aim: This study evaluated gender differences in mortality among patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) and examined whether disparities in SGLT2i and GLP-1RA dispensing contribute to mortality. Methods: The CARDIAB cohort included 138,397 patients with T2DM and established ASCVD, categorized by gender into male and female groups. The primary endpoint was all-cause mortality, and the secondary outcome was the dispensing rates of SGLT2i and GLP-1RA. Results: Of the 138,397 patients, 40.3% were women and 59.7% were men. The overall dispensing rates of SGLT2i and GLP-1RA were 37.1% and 23.4%, respectively, and were significantly lower among women compared with men for both SGLT2i (27.8% vs. 43.3%; p < 0.001) and GLP-1RA (21.3% vs. 24.9%; p < 0.001). Women exhibited higher mortality rates, as reflected by deaths per 10,000 patient-years (9724 vs. 7744; p < 0.001). However, in multivariable analysis, gender was not an independent predictor of mortality. Notably, the use of cardioprotective medications was strongly associated with reduced mortality, with the greatest benefit observed for SGLT2i (HR 0.307; 95% CI 0.299–0.316; p < 0.001) and GLP-1RA (HR 0.466; 95% CI 0.451–0.482; p < 0.001). Conclusions: Women with T2DM and ASCVD were treated less often with SGLT2i and GLP-1RA, therapies strongly associated with lower mortality. Their higher unadjusted mortality appears to reflect undertreatment rather than sex-related risk. Action is needed to improve the use of these cardioprotective medications, especially in women.


  • Procedural and Prognostic Implications of Guide Extension Catheter Use During Percutaneous Coronary Intervention: A Retrospective Cohort Study

    by Edward Itelman, Aviad Rotholz, Tamir Bental, Tsahi T. Lerman, Yeela Talmor‐Barkan, Hana Vaknin‐Assa, Amos Levi, Pablo Codner, Guy Witberg, Ran Kornowski, et al.

    Background: Guide extension catheters (GECs) have become an essential adjunctive tool in complex percutaneous coronary interventions (PCIs). GECs provide additional catheter support and stability, enhancing device deliverability. Aims: Our study aims to evaluate the technical and prognostic significance of the use of GECs in complex PCI. Methods: Our study included 23,299 PCI cases performed in a large tertiary center between 2010 and 2023. We assessed rates of procedural success with GEC. The primary clinical endpoint was all cause‐mortality. Other clinical endpoints included major adverse cardiac events (MACE) during follow‐up. Cox regression, multivariate analysis, and propensity score matching were used to compare GEC and non‐GEC PCI cases. Results: Of the 23,299 PCI cases in our study, 532 patients (2%) were treated utilizing GECs. The median age was 66 [IQR 58−75], and 88% were males. Successful PCI was performed in 96.2% of the total cohort, with similar rates in the GEC and non‐GEC group (94.9% vs. 96.2%, p  = 0.144). GEC was used more often in calcified, bifurcation, and unprotected left main lesions. Patients requiring the use of GEC had higher long‐term mortality rates (HR 1.86, 95% CI 1.54−2.23, p  < 0.001) and MACE events (HR 1.26, 95% CI 1.07−1.47, p  = 0.004). Multivariate adjustments, sensitivity analysis of complex‐PCI cases, and a propensity score‐matched model showed similar results. A landmark analysis showed no significant difference in 30‐day mortality but divergence of the survival curves after 30 days with increased mortality among the GEC cohort. Conclusions: Our study showed that patients who required GEC during PCI were successfully treated in the vast majority of cases, with similar short‐term results. However, the use of GEC is associated with a worse long‐term prognosis, reflecting a surrogate for sicker patients and procedural complexity, thus requiring careful follow‐up.

  • Open Access

    Impact of Baseline Atrial Fibrillation on Conduction Disturbances After TAVR: Insights from a Large Cohort Study

    by Ziad Arow, Omar Oliva, Laurent Bonfils, Laurent Lepage, Hana Vaknin-Assa, Abid Assali, Didier Tchetche, Nicolas Dumonteil

    Background: Pre-existing atrial fibrillation (AF) is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, evidence regarding its impact on the risk of permanent pacemaker (PPM) implantation and other conduction disturbances (CDs) after TAVR remains inconsistent. The aim of this study was to assess the effect of baseline heart rhythm on the risk of conduction abnormalities following TAVR. Methods: This study included patients with severe AS who underwent TAVR using either balloon-expandable (BEVs) or self-expanding valves (SEVs). The primary endpoint was the incidence of PPM implantation and new or worsening left bundle branch block (LBBB) after TAVR according to baseline rhythm (sinus rhythm vs. AF). Secondary endpoints were predictors of PPM implantation, LBBB, the occurrence of periprocedural stroke, and in-hospital mortality. Results: A total of 5195 TAVR patients were included: 3560 with baseline sinus rhythm and 1635 with baseline AF. PPM implantation was more frequent in patients with AF than in those with sinus rhythm (17% vs. 15%, p = 0.033), whereas new or worsening LBBB was less common (11% vs. 14%, p = 0.026). After adjustment with multivariable logistic regression, these associations were no longer statistically significant (PPM implantation: OR 1.156, 95% CI 0.969–1.379, p = 0.108; new or worsening LBBB: OR 0.826, 95% CI 0.676–1.010, p = 0.062). Independent peri-procedural predictors of PPM implantation included baseline first-degree AV block, pre-procedural RBBB, the use of self-expandable valves, implantation of larger valve sizes (≥23 mm), and the need for valve repositioning. Conclusions: In this large cohort, baseline AF was not associated with an increased risk of PPM implantation or new onset LBBB compared with sinus rhythm. These findings suggest that baseline rhythm alone should not be considered an independent predictor of PPM implantation or CDs following TAVR.


  • Open Access

    A TAVI Programme Without an On-Site Cardiac Surgery Department: A Single-Center Retrospective Study

    by Rami Barashi, Mustafa Gabarin, Ziad Arow, Ranin Hilu, Ilya Losin, Ivan Novikov, Karam Abd El Hai, Yoav Arnson, Yoram Neuman, Koby Pesis, et al.

    Background: Aortic stenosis (AS) is the most common valvular heart disease, associated with poor outcomes if left untreated. Current guidelines recommend that transcatheter aortic valve implantation (TAVI) procedures be performed in hospitals with an on-site cardiac surgery unit due to potential complications requiring surgical intervention. Objective: Based on our experience, we evaluated the feasibility and outcomes of implementing a TAVI program in a cardiology department without an on-site cardiac surgery unit, in collaboration with a remote hospital for surgical backup. Methods: The TAVI program involved pre- and post-procedural evaluations conducted at Meir Medical Center (Kfar Saba, Israel) with a remote surgical team available. The study population included 149 consecutive patients with severe aortic stenosis treated at the Meir valve clinic between November 2019 and December 2023. Procedures were performed by the center’s interventional cardiology team. Results: The mean age of the 149 patients was 80 ± 6 years, and 75 (50%) were female. The average STS score was 4.3, and the EuroSCORE II was 3.1. Among the patients, 68 (45%) were classified as New York Heart Association (NYHA) class III-IV. The valve types used included ACURATE neo2 (57 patients, 38%), Edwards SAPIEN 3 (43 patients, 28%), Evolut-PRO (41 patients, 27%), and Navitor (7 patients, 4%). There were no cases of moderate to severe paravalvular leak and no elevated post-implantation gradients, and there was no need for urgent cardiac surgery. One case of valve embolization was successfully managed percutaneously during the procedure. In-hospital follow-up revealed no deaths and only one major vascular complication. At one-year follow-up, six patients had died, with only one death attributed to cardiac causes. Conclusions: Our findings support the safe and effective performance of transfemoral TAVI in cardiology departments without on-site cardiac surgery, in collaboration with a remote surgical team. Further prospective, multicenter studies are warranted to confirm these results and guide broader clinical implementation of this practice.

  • Open Access

    TAVI Program in a Center Without On-Site Cardiac Surgical Department

    by Rami Barashi, Mustafa Gabarin, Ziad Arow, Ranin Hilu, Ilya Losin, Ivan Novikov, Karam Abdelhai, Yoav Arnson, Yoram Neuman, Koby Pesis, et al.

    Background: Aortic stenosis (AS) is the most common valvular heart disease, associated with poor outcomes if left untreated. Current guidelines recommend that transcatheter aortic valve implantation (TAVI) procedures be performed in hospitals with an on-site cardiac surgery unit due to potential complications requiring surgical intervention. This study aims to evaluate the feasibility and clinical outcomes of implementing a TAVI program at a cardiology department without an on-site cardiac surgery department, in collaboration with a remote hospital for surgical backup. Methods: The TAVI program involved pre- and post-procedural evaluations conducted at Meir Medical Center (Kfar Saba, Israel) with a remote surgical team available. The study population included 149 consecutive patients with severe aortic stenosis treated at the Meir valve clinic between November 2019 and December 2023. Procedures were performed by the center's interventional cardiology team. Results: The mean age of the 149 patients was 80 ± 6 years, and 75 (50%) were female. The average STS score was 4.3 and the EuroSCORE II was 3.1. Among the patients, 68 (45%) were classified as New York Heart Association (NYHA) class III-IV. Valve types used included Acurate-neo 2 (57 patients, 38%), Sapien-3 (43 patients, 28%), Evolut-PRO (41 patients, 27%), and Navitor (7 patients, 4%). There were no cases of moderate to severe paravalvular leak, no elevated post-implantation gradients, and no need for urgent cardiac surgery. One case of valve embolization was successfully managed percutaneously during the procedure. In-hospital follow-up revealed no deaths and only one major vascular complication. At one-year follow-up, six patients had died, with only one death attributed to cardiac causes. Conclusions: This study demonstrates that the transfemoral TAVI procedure can be safely and effectively performed in a cardiology department without an on-site cardiac surgery unit, provided there is collaboration with a remote surgical center. These findings suggest that expanding TAVI programs to centers without on-site cardiac surgery could increase access to this life-saving treatment for aortic stenosis.

  • Open Access

    The Impact of Sex on Cardiogenic Shock Outcomes Following ST Elevation Myocardial Infarction

    by Joshua H. Arnold, Leor Perl, Abid Assali, Pablo Codner, Gabriel Greenberg, Abid Samara, Avital Porter, Katia Orvin, Ran Kornowski, Hana Vaknin Assa

    Background: Cardiogenic shock (CS) remains the leading cause of ST elevation myocardial infarction (STEMI)-related mortality. Contemporary studies have shown no sex-related differences in mortality. Methods: STEMI-CS patients undergoing primary percutaneous coronary intervention (PPCI) were included based on a dedicated prospective STEMI database. We compared sex-specific differences in CS characteristics at baseline, during hospitalization, and in subsequent clinical outcomes. Endpoints included all-cause mortality and major adverse cardiac events (MACE). Results: Of 3202 consecutive STEMI patients, 210 (6.5%) had CS, of which 63 (30.0%) were women. Women were older than men (73.2 vs. 65.5% y, p < 0.01), and more had hypertension (68.3 vs. 52.8%, p = 0.019) and diabetes (38.7 vs. 24.8%, p = 0.047). Fewer were smokers (13.3 vs. 41.2%, p < 0.01), had previous PCI (9.1 vs. 22.3% p = 0.016), or required IABP (35.3 vs. 51.1% p = 0.027). Women had higher rates of mortality (53.2 vs. 35.3% in-hospital, p = 0.01; 61.3 vs. 41.9% at 1 month, p = 0.01; and 73.8 vs. 52.6% at 3 years, p = 0.05) and MACE (60.6 vs. 41.6% in-hospital, p = 0.032; 66.1 vs. 45.6% at 1 month, p = 0.007; and 62.9 vs. 80.3% at 3 years, p = 0.015). After multivariate adjustment, female sex remained an independent factor for death (HR-2.42 [95% CI 1.014–5.033], p = 0.042) and MACE (HR-1.91 [95% CI 1.217–3.031], p = 0.01). Conclusions: CS complicating STEMI is associated with greater short- and long-term mortality and MACE in women. Sex-focused measures to improve diagnosis and treatment are mandatory for CS patients.


  • Open Access

    Transcatheter Interventions for Atrioventricular Dysfunction in Patients with Adult Congenital Heart Disease: An International Case Series

    by Nili Schamroth Pravda, Hana Vaknin Assa, Lars Sondergaard, Vilhelmas Bajoras, Horst Sievert, Kerstin Piayda, Amos Levi, Guy Witberg, Yaron Shapira, Ashraf Hamdan, et al.

    Introduction: A substantial proportion of patients with adult congenital heart disease (ACHD) suffer from worsening valvular dysfunction in adulthood. Transcatheter valve interventions can offer a therapeutic alternative to surgery for those at high surgical risk. There is emerging but limited data on transcatheter interventions for atrioventricular (AV) valve dysfunction in patients with ACHD. Methods: We compiled an international collaborative multi-center registry focusing on adult patients with congenital heart disease undergoing transcatheter AV valve interventions (repair or replacement). Included were patients from three international centers who underwent procedures between 2016 and 2022. Demographic, clinical, and procedural data were compiled. Results: Nine patients with ACHD underwent AV valve interventions. The median age was 48 years (IQR (37; 56), 55% women). At baseline, seven patients (78%) were in NYHA functional class III and two (22%) were in NYHA functional class II. The diagnosis of ACHD varied. Three valve interventions were performed on the subpulmonary AV valve and six on the systemic AV valve. The primary valvular pathology was regurgitation (six patients, 78%). Five procedures were valve-in-valve interventions, and four procedures were transcatheter edge-to-edge repair procedures. There were no major complications or peri-procedural complications or peri-procedural mortality. One patient developed a suspected non-obstructive thrombus on the valve that was medically treated. One patient did not improve clinically following the procedure and underwent a heart transplant, one patient died 6 months following the procedure due to a cardiovascular implantable electronic device infection. At one year, six patients were in NYHA functional class I, and one patient was in NYHA functional class III. In conclusion, transcatheter AV heart valve interventions are feasible and safe procedures in carefully selected ACHD patients. These procedures can offer an effective treatment option in these younger patients with high surgical risk.


  • Open Access

    Reticulated Platelets and Their Relationship with Endothelial Progenitor Cells during the Acute Phase of ST-Elevation Myocardial Infarction

    by Nili Schamroth Pravda, Mark Kheifets, Maya Wiessman, Dorit Leshem-Lev, Hana Vaknin Assa, Ran Kornowski, Yeela Talmor-Barkan, Leor Perl

    Introduction: Endothelial progenitor cells (EPC) and reticulated platelets (RP) have central roles in the thrombotic and angiogenetic interactions during ST-elevation myocardial infarction (STEMI). The EPC and RP response in patients with STEMI treated by primary percutaneous intervention (PPCI) has not yet been investigated. Methods: We assessed EPC quantification by the expression of CD133+ and CD34+, and EPC function by the capacity of the cells to form colony-forming units (CFU) and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) during the acute phase of STEMI. These measurements were correlated with RP at baseline and after 24 h following PPCI. Results: Our cohort included 89 consecutive STEMI-diagnosed patients enrolled between December 2018 and July 2021. At baseline, there was a strong positive correlation between reticulated platelet quantity and MTT levels (R = 0.766 and R2 = 0.586, p < 0.001), CD34+ levels (R = 0.602, and R2 = 0.362, p < 0.001); CD133+ levels (R = 0.666 and R2 = 0.443, p < 0.001) and CFU levels (R = 0.437, R2 = 0.191, p < 0.001). The multiple linear regression showed that levels of MTT (adjusted R2 = 0.793; p < 0.001), CD34+ and CD133+ (adjusted R2 = 0.654; p < 0.001 and adjusted R2 = 0.627; p < 0.001, respectively) had strong independent correlations with RP response. At 24 h after PPCI, the correlation between RP quantity and EPC markers was not significant, except for MTT levels (R = 0.465, R2 = 0.216, p < 0.001). Conclusions: In patients with STEMI, higher levels of RP at baseline are significantly correlated with a more potent EPC response. The translational significance of these findings needs further investigation.